Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Ethical Drug Sales Down 8.1% in September: Crecon
November 12, 2018
- Avastin Tops Japan Sales Ranking for 3 Months on End: Encise Snapshot
November 12, 2018
- Nippon Kayaku’s Herceptin Biosimilar to Foray into Breast Cancer Arena, following Daiichi Sankyo, Pfizer
November 12, 2018
- Eisai Launches Full-Scale Operations at New China Plant, Doubling Production Capacity
November 12, 2018
- EA Pharma Pairs Up with 6 Institutions on Joint Research on Novel Antibody for Crohn’s Disease
November 9, 2018
- Maviret Retains Top Spot in Japan Drug Ranking in July-September: IQVIA
November 8, 2018
- Nippon Shinyaku Preparing for Clinical Studies of 5 Oligonucleotide Drugs to Cover 50% of DMD Patients: Pres.
November 8, 2018
- Takeda Launches Entyvio in Japan for Ulcerative Colitis
November 8, 2018
- Aspen Taking Over Anexate from Astellas
November 7, 2018
- Kyowa Kirin License Novel Blood Cancer Treatment from US Company
November 7, 2018
- EMA Accepts Quizartinib Application, with Accelerated Assessment Status: Daiichi Sankyo
November 7, 2018
- Balancing Act: All Eyes on Nesp Biosame Pricing before June 2019 Listing, Biosimilars to Follow in November
November 5, 2018
- Opdivo-Yervoy Combo Gets RCC Nod in Taiwan
November 5, 2018
- Kyowa Kirin to Start US PI Study on IDO Inhibitor-Bavencio Combo
November 5, 2018
- 8 Major Drug Makers See Flat Sales in 1st Half; Overseas Growth Continues to Compensate for Slumping Japan Revenue
November 5, 2018
- Pfizer Files Vyndaqel for Sakigake-Designated Transthyretin Amyloid Cardiomyopathy Indication in Japan
November 5, 2018
- JCR’s Fabrazyme Biosimilar to Enter NHI Price List as Early as November
November 5, 2018
- Takeda Unveils Estimated Net Debt, Goodwill Post Shire Integration
November 2, 2018
- Eisai, Merck to Start Lenvima Commercial Collaboration in Major Markets by March-End
November 2, 2018
- Eisai’s 1st Half Operating Profit Zooms 74% on Lenvima Boon
November 2, 2018
ページ
International regulators are increasingly moving away from comparative efficacy studies (CES) in biosimilar development — long considered a default requirement…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…